• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology

    12/16/24 8:31:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care
    Get the next $BEAT alert in real time by email
    • First cable-free, ambulatory ECG that captures the heart's electrical signals from three distinct directions for high-fidelity data collection and advanced diagnostics
    • Patients can have the credit card-sized device with them at all times, ready to record an ECG whenever they feel symptoms and reduce delays in care
    • Company to initiate Early Access Program to gain important patient and physician feedback on the use of the system in preparation for commercial launch

    HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance of the HeartBeam system for comprehensive arrhythmia assessment. With its patented design, the HeartBeam device is the first-of-its-kind to receive FDA clearance. As a high-fidelity electrocardiogram (ECG) system with a credit card-sized form factor and cable-free design, it captures heart signals from three distinct directions for actionable heart health information.

    When a patient feels symptoms, the HeartBeam patient app guides them through the process of placing the device on their chest and capturing a 30-second recording. Once a recording is taken, the signals are sent to the cloud, processed and sent to a physician for review. The physician reviews the ECG recording in the context of the patient's symptoms and medical history, then follows up with the patient on next steps. The Company plans to initiate an Early Access Program and is creating a waitlist of interested patients and physicians.

    To Join the Waitlist, Sign Up Here

    Watch a Video of How the HeartBeam System Works

    "It's well documented that patients who delay seeking care for their cardiac symptoms face worse clinical outcomes. The ability for patients to capture high-fidelity ECG signals from three directions wherever they are when symptoms occur will help patients get the care they need in a timelier manner," said Robert Eno, Chief Executive Officer, HeartBeam. "The FDA clearance of our technology is a significant milestone for the Company that brings us one step closer to fulfilling our vision of providing unprecedented cardiac insights to individuals and physicians."

    The FDA clearance is foundational and will serve as the basis for future submissions as the Company strives to simplify the access of intelligent and actionable 12-lead ECGs for both patients and physicians. Future planned advances include:

    • Synthesized 12-lead ECG: The HeartBeam system is designed to be capable of synthesizing the heart's signals collected from three directions into a 12-lead ECG using a personalized transformation matrix as demonstrated in this pilot study.
    • AI-Based Classification Algorithms: Data presented earlier this year demonstrated that HeartBeam's deep learning algorithm has the potential to greatly improve the detection of atrial flutter, even outperforming cardiologists in detecting some arrhythmias.
    • Heart Attack Detection: A study published in JACC: Advances showed that HeartBeam's ambulatory technology is comparable to a standard 12-lead ECG in identifying coronary occlusions and is highly accurate (Area Under the Curve of 95%). Another feasibility study highlighted the potential of HeartBeam's technology to calculate a heart attack risk-score to assess chest pain remotely.

    HeartBeam's proprietary technology has the potential to unlock valuable diagnostic and predictive insights. The ease of collecting higher-fidelity ECG signals will enable patients to gather a series of recordings over time. The Company aims to leverage AI to analyze this rich set of data, delivering a longitudinal view of a patient's cardiac health and predicting cardiac conditions before symptoms appear. HeartBeam believes its groundbreaking technology presents a transformative opportunity to bring about a paradigm shift in cardiovascular care for millions of patients globally.

    About HeartBeam, Inc.

    HeartBeam, Inc. (NASDAQ:BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first ever cable-free synthesized 12-lead ECG capable of capturing the heart's electrical signals from three distinct directions. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. The Company holds 13 US and 4 international issued patents related to technology enablement. For additional information, visit HeartBeam.com.

    About the HeartBeam System

    The HeartBeam System is a portable non-invasive recorder intended to record, store, and transfer a patient's 3-Lead (in three-directions) electrocardiogram (ECG) acquired from 5 electrodes. The device is intended to be used by adult patients in either a clinical setting or at home. The device does not conduct cardiac analysis and can be used with an ECG Viewer software system for manual interpretation of non-life-threatening arrhythmias by a physician or healthcare professional. For full safety information, see the full Instructions for Use or Clinician Portal Manual.

    Forward-Looking Statements

    All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241216069324/en/

    Get the next $BEAT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BEAT

    DatePrice TargetRatingAnalyst
    12/20/2021$9.00Speculative Buy
    Benchmark
    More analyst ratings

    $BEAT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HeartBeam Announces Two New U.S. Patents, Powering Forward Its Robust Patent Portfolio

      First patent significantly advances intellectual property for HeartBeam's credit card-sized ECG device, bolstering both the defensive and offensive moat around the company's core technology Second patent expands the use of risk-based diagnostic algorithms into HeartBeam's product portfolio around wearable devices HeartBeam now has 20 issued patents worldwide, cementing Company's leadership in cardiac monitoring innovation HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced the addition of two new U.S. patents, reinforcing its core intellectual property position and enabling futur

      5/6/25 7:00:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • HeartBeam Appoints CEO Robert Eno to Board of Directors to Support U.S. Commercialization and Growth

      Board expansion reflects Company's commitment to leadership and innovation in remote cardiac monitoring HeartBeam, Inc., (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced the appointment of Chief Executive Officer, Robert Eno, to its Board of Directors. As the Company continues to make significant advancements towards commercial readiness, the Board elected to expand from eight to nine members to accommodate this addition. Mr. Eno joined HeartBeam as President in January 2023 and was appointed CEO in October 2024. With over 30 years of experience in the medical technology industry, he has a proven

      5/5/25 7:00:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • HeartBeam to Host First Quarter 2025 Results Conference Call on Tuesday, May 13, 2025 at 4:30 p.m. Eastern Time

      HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Tuesday, May 13, 2025 at 4:30 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2025, and will be providing updates on regulatory initiatives, commercial-readiness activities and anticipated milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be viewed during the web

      5/1/25 8:31:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    Financials

    Live finance-specific insights

    See more
    • HeartBeam to Host First Quarter 2025 Results Conference Call on Tuesday, May 13, 2025 at 4:30 p.m. Eastern Time

      HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Tuesday, May 13, 2025 at 4:30 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2025, and will be providing updates on regulatory initiatives, commercial-readiness activities and anticipated milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be viewed during the web

      5/1/25 8:31:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • HeartBeam to Host Fourth Quarter Full Year 2024 Results Conference Call on Thursday, March 13, 2025 at 4:30 p.m. Eastern Time

      HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Thursday, March 13, 2025 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2024, and will be providing updates on regulatory initiatives, commercial-readiness activities and anticipated milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be

      2/27/25 8:31:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • HeartBeam Reports Third Quarter 2024 Results

      Continued Clinical and Regulatory Progress on the HeartBeam System Key Appointments to Management Team Completed as Part of Planned Evolution in Preparation for US Commercialization Strengthening Clinical Evidence Base, with Two Additional Studies to be Presented at the American Heart Association Conference in November 2024 Management to Host Webcast and Conference Call Today at 4:30 p.m. ET HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has reported its financial and operational results for the third quarter ended September 30, 2024. Third Quarter & Subsequent 2024 Operational Highlights

      11/7/24 4:05:00 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Benchmark initiated coverage on BioTelemetry with a new price target

      Benchmark initiated coverage of BioTelemetry with a rating of Speculative Buy and set a new price target of $9.00

      12/20/21 7:19:06 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    SEC Filings

    See more
    • Heartbeam Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - HeartBeam, Inc. (0001779372) (Filer)

      5/5/25 10:00:43 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • Heartbeam Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - HeartBeam, Inc. (0001779372) (Filer)

      4/25/25 3:38:24 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-K filed by Heartbeam Inc.

      10-K - HeartBeam, Inc. (0001779372) (Filer)

      3/13/25 4:20:54 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ferrari Richard bought $50,000 worth of shares (29,412 units at $1.70), increasing direct ownership by 20% to 179,136 units (SEC Form 4)

      4 - HeartBeam, Inc. (0001779372) (Issuer)

      2/21/25 8:00:22 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • CFO Cruickshank Tim bought $30,000 worth of shares (17,647 units at $1.70) (SEC Form 4)

      4 - HeartBeam, Inc. (0001779372) (Issuer)

      2/21/25 7:55:14 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Cruickshank Tim

      4 - HeartBeam, Inc. (0001779372) (Issuer)

      5/1/25 11:06:06 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Eno Robert Paul

      4 - HeartBeam, Inc. (0001779372) (Issuer)

      5/1/25 11:05:46 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Technology Officer Persen Kenneth Harry

      4 - HeartBeam, Inc. (0001779372) (Issuer)

      5/1/25 11:03:46 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    Leadership Updates

    Live Leadership Updates

    See more

    $BEAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • HeartBeam Appoints CEO Robert Eno to Board of Directors to Support U.S. Commercialization and Growth

      Board expansion reflects Company's commitment to leadership and innovation in remote cardiac monitoring HeartBeam, Inc., (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced the appointment of Chief Executive Officer, Robert Eno, to its Board of Directors. As the Company continues to make significant advancements towards commercial readiness, the Board elected to expand from eight to nine members to accommodate this addition. Mr. Eno joined HeartBeam as President in January 2023 and was appointed CEO in October 2024. With over 30 years of experience in the medical technology industry, he has a proven

      5/5/25 7:00:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology

      First cable-free, ambulatory ECG that captures the heart's electrical signals from three distinct directions for high-fidelity data collection and advanced diagnostics Patients can have the credit card-sized device with them at all times, ready to record an ECG whenever they feel symptoms and reduce delays in care Company to initiate Early Access Program to gain important patient and physician feedback on the use of the system in preparation for commercial launch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the US Food and Drug Administration (FDA) has granted 510(k) cl

      12/16/24 8:31:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • HeartBeam Appoints Robert Eno as Chief Executive Officer in Preparation for US Commercialization

      Industry leader brings extensive experience in developing go-to-market strategies for breakthrough products and delivering growth Founder and current CEO Branislav Vajdic named President to focus on advancing the Company's groundbreaking vector-based technology for heart health, including AI applications HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful insights wherever the patient is, announced that Robert Eno has been appointed Chief Executive Officer (CEO), effective Monday, October 21, 2024. The seasoned MedTech executive joined HeartBeam as President in January 2023 and will lead as the Company continues to work

      10/17/24 8:31:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D filed by Heartbeam Inc.

      SC 13D - HeartBeam, Inc. (0001779372) (Subject)

      10/25/23 4:01:55 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D filed by Heartbeam Inc.

      SC 13D - HeartBeam, Inc. (0001779372) (Subject)

      8/28/23 4:26:34 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D filed by Heartbeam Inc.

      SC 13D - HeartBeam, Inc. (0001779372) (Subject)

      6/2/23 2:36:13 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care